multiple myeloma clinical trials results

Elotuzumab Lenalidomide Dexamethasone versus Lenalidomide + Dexamethasone
ELOQUENT - 1, 0 NCT01335399	versus	Newly Diagnosed, Previously Untreated Multiple Myeloma	open label USA
carfilzomib versus bortezomib
ENDEAVOR, 2016 NCT01568866	carfilzomib with dexamethasone versus bortezomib with dexamethasone	patients with relapsed or refractory multiplemyeloma who had one to three previous treatments	open-label
carfilzomib versus bortezomid
ECOG-ACRIN, NCT01863550	versus
CLARION, NCT01818752	versus
carfilzomib versus low-dose corticosteroids
FOCUS, 2017 NCT01302392	carfilzomib monotherapy versus low-dose corticosteroids and optional cyclophosphamide	relapsed and refractory multiple myeloma (RRMM)	open-label
carfilzomib versus placebo (on top lenalidomide and dexamethasone)
ASPIRE, 2015 NCT01080391	carfilzomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone	patients with relapsed multiple myeloma	open-label
carfilzomib lenalidomide dexamethasone versus lenalidomide and dexamethasone alone
ASPIRE, 2014 NCT01080391	carfilzomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone	patients with relapsed multiple myeloma	open-label
CTDa versus MP
MRC Myeloma IX, ISRCTN68454111	CTDa versus MP
elotuzumab versus placebo (on top lenalidomide and dexamethasone)
ELOQUENT 2, 2015 NCT01239797	elotuzumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone	patients with Relapsed or Refractory Multiple Myeloma	open-label
Elotuzumab Lenalidomide Dexamethasone versus Lenalidomide + Dexamethasone
ELOQUENT - 2, 0 NCT01239797	Lenalidomide + Dexamethasone +Elotuzumab versus Lenalidomide + Dexamethasone	patients with Relapsed or Refractory Multiple Myeloma
MPR + CPR versus Rd
NR 2013,	MPR + CPR versus Rd
MPR+R versus MP
MM-015, NCT00405756	MPR+R versus MP
MPR+R versus MPT+T
EIA06 (NCT00602641), 0 NCT00602641	MPR+R versus MPT+T
MPT versus MP
IFM 01/01,	MPT versus MP
IFM 99/06, NCT00367185	MPT versus MP
NCT01274403, NCT01274403	MPT versus MP
MPT+T versus MP
GIMEMA, NCT00232934	MPT+T versus MP
HOVON 49, ISRCTN90692740	MPT+T versus MP
NMSG,	MPT+T versus MP
TMSG, NCT00934154	MPT+T versus MP
PCAB+IFN-2a versus PCAB
NR 1997,	PCAB+IFN-2a versus PCAB
pembrolizumab + pomadoline + dexamethasone versus pomadoline + dexamethasone
KEYNOTE-183, 2018 NCT02576977	pembrolizumab, Pomalidomide and low-dose Dexamethasone versus Pomalidomide and low-dose Dexamethasone	refractory or relapsed and refractory Multiple Myeloma (rrMM)	open-design Follow-up duration: 7.8 mo / 8.6 mo (median)
pembrolizumab, lenalidomide, dexametahsone versus lenalidomide, dexamethasone
KEYNOTE-185, 2018 NCT02579863	versus lenalidomide and low-dose dexamethasone	newly diagnosed and treatment naïve Multiple Myeloma who are ineligible for autologous stem cell transplant	open-design
Rd ou Rd18 versus MPT
FIRST , NCT00689936	Rd ou Rd18 versus MPT
VMP versus MP
VISTA, NCT00111319	VMP versus MP
VMP + siltuximab versus VMP
NCT00911859, NCT00911859	VMP + siltuximab versus VMP
VMPT+VT versus VMP
NR 2010,	VMPT+VT versus VMP